skip to main content
Menu
ijic-11.10.2023-1

International Journal of Industrial Chemistry (IJIC)

Editor-in-Chief: Akbar Esmaeili, PhD

Online ISSN: 2228-5547

Print ISSN: 2228-5970

Publishes Quarterly

Original Article
Serum miR-589-5p is related to biochemical recurrence after radical prostatectomy in prostate cancer patients

miRNAs manifested aberrantly suggest an association with prostate cancer (PCa) progression, such as biochemical recurrence (BCR). Therefore, we explored the correlation between serum miR-589-5p and postoperative BCR in PCa patients. Sixty PCa patients who underwent radical prostatectomy were included, and another 60 matched healthy male volunteers served as the normal control. Serum miR-589-5p was detected […]

Original Article
Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer

This research aimed to investigate the safety and efficacy of inhibitors of programmed cell death 1 and its ligand in the postoperative chemotherapy for advanced colorectal cancer. Patients with advanced colorectal cancer treated in our hospital from June 2019 to June 2021 were included (23 patients receiving Apatinib served as the control group and 28 […]

Original Article
Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer

To investigate the clinical efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel (Abraxane) combined with S-1 after radical pancreatic cancer surgery. A total of 133 patients who underwent adjuvant chemotherapy with the FOLFIRINOX (60 cases) or Abraxane combined with S-1 (73 cases) after radical resection pancreatic cancer were screened. According to the follow-up data, recurrence […]

Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer
Original Article
Effects of PDCA cycle management on patients with acute myelocytic leukemia receiving decitabine combined with low dose idarubicin and cytarabine

Acute myeloid leukemia (AML) is a hematologic neoplasm that occurs in adults, especially in the elderly. This study was performed to investigate the impact of a plan, do, check, act (PDCA)-based care management model on the clinical outcomes and quality of life of patients with AML receiving the decitabine (DCA) regimen in combination with low […]

Effects of PDCA cycle management on patients with acute myelocytic leukemia receiving decitabine combined with low dose idarubicin and cytarabine